What is BMRA's current stock price?

BMRA (Biomerica, Inc.) is currently trading at $2.49 with a market cap of $7.7M.

What sector is Biomerica, Inc. in?

Biomerica, Inc. (BMRA) operates in the Healthcare sector, specifically in the Medical - Devices industry.

InvestLog

BMRA Biomerica, Inc.

Healthcare

$2.49+2.05%ClosedMarket Cap: $7.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.26

P/S

1.78

EV/EBITDA

-1.70

DCF Value

$-69.60

FCF Yield

-41.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

4.3%

Operating Margin

-123.7%

Net Margin

-96.5%

ROE

-98.1%

ROA

-85.6%

ROIC

-152.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$987.0K	$-1.3M	$—
Q2 null	$1.2M	$-1.3M	$—
Q1 null	$1.4M	$2.0K	$—
Q4 null	$749.0K	$-1.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Chin Ericdirector

SellWed Jan 28

MOATAZEDI DAVIDdirector

SellWed Dec 31

Lu Garyofficer: Chief Financial Officer

SellWed Dec 31

Irani Zackary S.director, officer: Chief Executive Officer

SellWed Dec 31

Gary M. Huffdirector

SellWed Dec 31

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.28

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Peers